- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
The dosage of Ruxolitinib should be adjusted according to the indications, patient platelet count, and treatment response. The whole tablet sho...
Ruxolitinib has been launched in China and is suitable for the treatment of hematological diseases such as myelofibrosis and polycythemia vera....
Mobocertinib has not yet been officially listed in Chinese Mainland. When patients need to obtain it through overseas channels, they should pay...
Ruxolitinib, as a JAK1/2 inhibitor, has shown significant efficacy in hematological diseases such as myelofibrosis and polycythemia vera. Its ...
The dosage of Mobocetinib should be determined according to the indications and individual patient conditions. It is mainly used for non-small ...
Finelinone is a selective nonsteroidal mineralocorticoid receptor antagonist, which is mainly used to treat type 2 diabetes related chronic kid...
Mobocetinib is an oral EGFR inhibitor primarily used to treat non-small cell lung cancer carrying EGFR exon 20 insertion mutations. The standar...
Finelinone is a selective nonsteroidal mineralocorticoid receptor antagonist, which is mainly used to treat chronic kidney disease associated w...
Ivosidenib is an IDH1 inhibitor used to treat relapsed/refractory acute myeloid leukemia (AML) patients carrying IDH1 mutations or newly diagno...
Pemigatinib is an FGFR inhibitor used to treat advanced cholangiocarcinoma patients carrying FGFR2 fusion or rearrangement. The treatment cours...
